全文获取类型
收费全文 | 711篇 |
免费 | 81篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 2篇 |
妇产科学 | 4篇 |
基础医学 | 107篇 |
口腔科学 | 15篇 |
临床医学 | 29篇 |
内科学 | 84篇 |
皮肤病学 | 7篇 |
神经病学 | 11篇 |
特种医学 | 3篇 |
外科学 | 38篇 |
综合类 | 33篇 |
预防医学 | 14篇 |
眼科学 | 1篇 |
药学 | 52篇 |
中国医学 | 4篇 |
肿瘤学 | 395篇 |
出版年
2024年 | 3篇 |
2023年 | 13篇 |
2022年 | 34篇 |
2021年 | 34篇 |
2020年 | 21篇 |
2019年 | 20篇 |
2018年 | 16篇 |
2017年 | 32篇 |
2016年 | 23篇 |
2015年 | 84篇 |
2014年 | 50篇 |
2013年 | 44篇 |
2012年 | 26篇 |
2011年 | 26篇 |
2010年 | 36篇 |
2009年 | 42篇 |
2008年 | 30篇 |
2007年 | 27篇 |
2006年 | 27篇 |
2005年 | 21篇 |
2004年 | 26篇 |
2003年 | 27篇 |
2002年 | 19篇 |
2001年 | 19篇 |
2000年 | 20篇 |
1999年 | 13篇 |
1998年 | 14篇 |
1997年 | 10篇 |
1996年 | 11篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 4篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 3篇 |
1982年 | 1篇 |
1979年 | 2篇 |
排序方式: 共有806条查询结果,搜索用时 15 毫秒
101.
102.
摘要:目的:研究人胚胎骨髓间充质干细胞(fetal mesenchymal stem cells, FMSC)及其突变肿瘤细胞F6死亡相关蛋白激酶(deathassociated protein kinase,DAPK)基因的表达及启动子区域甲基化。 方法:用RT-PCR和甲基化特异性PCR(methylationspecific PCR, MS-PCR)技术对FMSC及F6细胞系DAPK 基因的表达和启动子甲基化状态进行检测,并对甲基化产物测序鉴定。 结果:DAPK基因在FMSC中表达而在F6中不表达。通过MS-PCR检测证实F6中DAPK基因发生甲基化,FMSC中DAPK基因发生未完全甲基化。 结论:DAPK基因启动子区域发生甲基化可能是促使其基因表达下调的重要机制,在FMSC突变成F6肿瘤细胞过程中发挥重要作用。 相似文献
103.
ADAMTS4 and its proteolytic fragments differentially affect melanoma growth and angiogenesis in mice
Nithya Rao Zhiyuan Ke Hongrui Liu Chao‐Jin Ho Saran Kumar Wei Xiang Yizhun Zhu Ruowen Ge 《International journal of cancer. Journal international du cancer》2013,133(2):294-306
The metalloproteinase ADAMTS4 (ADAMTS, a disintegrin‐like and metalloproteinase with thrombospondin motif)/aggrecanase‐1 is highly expressed in cartilage and has been implicated in human arthritis. Although abundantly expressed in many types of cancer, its role in cancer remains unknown. In this work, we demonstrate for the first time that full‐length ADAMTS4 and its catalytically more active N‐terminal 53 kDa autocatalytic fragment both promote B16 melanoma growth and angiogenesis in mice. In contrast, overexpression of its catalytically inactive E362A mutant or truncated fragments containing only the C‐terminal ancillary domains suppresses melanoma growth and angiogenesis under similar conditions. Structure–function mapping revealed that the single thrombospondin‐type 1 repeat domain is essential and sufficient for the antitumorigenic activity displayed by the catalytically inactive ADAMTS4 isoforms. Suppression of tumor growth and angiogenesis in mice is accompanied by a significant increase in tumor cell apoptosis, whereas tumor cell proliferation is not affected. Importantly, we identified and demonstrated the presence of novel proteolytic fragments of ADAMTS4 containing essentially only the C‐terminal ancillary domains in cultured cells, and also in human cancer tissues, coexisting with full‐length and catalytically active N‐terminal fragments. The contrasting functions toward tumor growth in mice by the wild‐type proteinase and its catalytically inactive mutant correlate with their contrasting influences on angiogenesis signaling pathway molecules in B16 melanoma in mice. Our results suggest a complex role for ADAMTS4 in cancer with the functional balance of protumorigenic and antitumorigenic isoforms likely to act as an important parameter in determining the net influence of this metalloproteinase on tumor growth in vivo. 相似文献
104.
Xianhui Wang Heng Lu Tianshu Li Lin Yu Gang Liu Xu Peng Jihe Zhao 《American journal of cancer research》2013,3(4):356-373
The properties of stem cells can be induced during the epithelial to mesenchymal transition (EMT). The responsible molecular mechanisms, however, remain largely undefined. Here we report the identification of the microRNA-146a (miR-146a) as a common target of Krüppel-like factor 8 (KLF8) and TGF-β, both of which are known EMT-inducers. Upon KLF8 overexpression or TGF-β treatment, a significant portion of the MCF-10A cells gained stem cell traits as demonstrated by an increased expression of CD44high/CD24low, activity of aldehyde dehydrogenase (ALDH), mammosphere formation and chemoresistance. Along with this change, the expression of miR-146a was highly upregulated in the cells. Importantly, we found that miR-146a was aberrantly co-overexpressed with KLF8 in a panel of invasive human breast cancer cell lines. Ectopic expression of KLF8 failed to induce the stem cell traits in the MCF-10A cells if the cells were pre-treated with miR-146a inhibitor, whereas overexpression of miR-146a in the MCF-10A cells alone was sufficient to induce the stem cell traits. Co-staining and luciferase reporter analyses indicated that miR-146a targets the 3’-UTR of the Notch signaling inhibitor NUMB for translational inhibition. Overexpression of KLF8 dramatically potentiated the tumorigenecity of MCF-10A cells expressing the H-Ras oncogene, which was accompanied by a loss of NUMB expression in the tumors. Taken together, this study identifies a novel role and mechanism for KLF8 in inducing pro-tumorigenic mammary stem cells via miR-146a potentially by activating Notch signaling. This mechanism could be exploited as a therapeutic target against drug resistance of breast cancer. 相似文献
105.
106.
《Expert review of anticancer therapy》2013,13(7):1133-1145
Cancer stem cells (CSCs) have provided new insights into the tumorigenesis and metastatic potential of cancer. The discovery of CSCs has provided many new insights into the complexities of cancer therapy: tumor initiation, treatment resistance, metastasis, recurrence, assessment of prognosis and prediction of clinical course. Recent rapid advances in molecular analysis have contributed to the better understanding of the molecular attributes and pathways that give CSCs their unique attributes. Use of these molecular techniques has facilitated elucidation of specific surface markers and pathways that favor propagation of CSCs – allowing for targeted therapy. Furthermore, it has been discovered that a specific microenvironment, or niche, is essential for the genesis of tumors from CSCs. Therapeutic strategies that alter these microenvironments compromise CSC proliferation and constitute another method of targeted cancer therapy. We review the clinical and therapeutic implications of CSCs, with a focus on treatment resistance and metastasis, and the emerging approaches to target CSCs and their microenvironments in order to attain improved outcomes in cancer. It is noteworthy that CSCs are the only cells capable of sustaining tumorigenesis; however, the cell of origin of cancer, in which tumorigenesis is initiated, may be distinct from CSCs that propagate the tumor. 相似文献
107.
Moran Amit Shorook Na'ara Eran Fridman Euvgeni Vladovski Tanya Wasserman Neta Milman Ziv Gil 《International journal of cancer. Journal international du cancer》2019,144(12):3014-3022
Pancreatic ductal adenocarcinoma (PDA) remains a deadly disease, affecting about 40,000 individuals in the United States annually. We aimed to characterize the role of RET as a co-driver of pancreas tumorigenesis. To assess the role of RET as a co-driver of PDA, we generated a novel triple mutant transgenic mouse based on the cre-activated p53R172H gene and a constitutively active RET M919T mutant (PRC). Survival analysis was performed using Kaplan–Meier analysis. Study of human PDA specimens and Pdx-1-Cre/KrasG12D /p53R172H (KPC) mice revealed that RET is upregulated during pancreas tumorigenesis, from inception through precursor lesions, to invasive cancer. We demonstrated that activation of RET is capable of inducing invasive pancreatic carcinomas in the background of the P53 inactivation mutation. Compared to KPC mice, PRC animals had distinct phenotypes, including longer latency to tumor progression, longer survival, and the presence of multiple macrometastases. Enhanced activation of the MAPK pathway was observed as early as the PanIN 2 stage. Sequencing of the exonic regions of KRAS in PRC-derived PDA cells revealed no evidence of KRAS mutations. RET can be an essential co-driver of pancreatic tumorigenesis in conjugation with KRAS activity. These data suggest that RET may be a potential target in the treatment of PDA. 相似文献
108.
Andrea Lunardi Kaitlyn A. Webster Antonella Papa Bhavik Padmani John G. Clohessy Roderick T. Bronson Pier Paolo Pandolfi 《Oncotarget》2014,5(4):894-900
The PI3K/AKT pathway governs a plethora of cellular processes, including cell growth, proliferation, and metabolism, in response to growth factors and cytokines. By acting as a unique lipid phosphatase converting phosphatidylinositol-3,4,5,-trisphosphate (PIP3) to phosphatidylinositol-4,5,-bisphosphate (PIP2), phosphatase and tensin homolog (PTEN) acts as the major cellular suppressor of PI3K signaling and AKT activation. Recently, PI3K mutations and loss/mutation of PTEN have been characterized in human gallbladder tumors; whether aberrant PTEN/PI3K pathway plays a causal role in gallbladder carcinogenesis, however, remains unknown. Herein we show that in mice, deregulation of PI3K/AKT signaling is sufficient to transform gallbladder epithelial cells and trigger fully penetrant, highly proliferative gallbladder tumors characterized by high levels of phospho-AKT. Histopathologically, these mouse tumors faithfully resemble human adenomatous gallbladder lesions. The identification of PI3K pathway deregulation as both an early event in the neoplastic transformation of the gallbladder epithelium and a main mechanism of tumor growth in Pten heterozygous and Pten mutant mouse models provides a new framework for studying in vivo the efficacy of target therapies directed against the PI3K pathway, as advanced metastatic tumors are often addicted to “trunkular” mutations. 相似文献
109.